China Urged to Prioritize Economy Over Territorial Ambitions, Says Taiwan’s President Lai 
Asia’s IPO Market Set for Strong Growth as China and India Drive Investor Diversification 
Northwestern University to Restore Research Funding Under $75 Million Agreement with U.S. Government 
Dollar Holds Steady as Markets Shift Focus to 2026 Rate Cut Expectations 
Amazon Italy Pays €180M in Compensation as Delivery Staff Probe Ends 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
Bolsonaro Detained Over Alleged Escape Risk After Ankle Monitor Tampering 
U.S. Justice Department Orders Intensified Probe Into Antifa and Domestic Extremist Groups 
Singapore Court Allows $2.7 Billion 1MDB Lawsuit Against Standard Chartered to Proceed 
Gold Prices Edge Higher as Markets Await Key U.S. PCE Inflation Data 
Asian Markets Stabilize as Wall Street Rebounds and Rate Concerns Ease 
IMF Deputy Dan Katz Visits China as Key Economic Review Nears 
Netanyahu Seeks Presidential Pardon Amid Ongoing Corruption Trial 
Asian Currencies Edge Higher as Markets Look to Fed Rate Cut; Rupee Steadies Near Record Lows 
Gold Prices Steady as Markets Await Key U.S. Data and Expected Fed Rate Cut 
Asian Markets Mixed as RBI Cuts Rates and BOJ Signals Possible Hike 
U.S. Futures Steady as Rate-Cut Bets Rise on Soft Labor Data 
Johnson & Johnson disclosed that it spent $800 million in settling "substantially all" of the roughly 9,000 cases by men who claimed having developed excessive breast tissue in using the company's antipsychotic drug Risperdal.
The company said it reached the agreement with lawyers handling the cases, including a lawsuit in Philadelphia by Maryland resident Nicholas Murray, who was awarded an $8 billion in punitive damage by a jury award in 2019. A judge has since reduced the award to $6.8 million.
The lawsuits, filed in Pennsylvania, California, and Missouri, generally accused J&J of failing to warn of the risk called gynecomastia associated with Risperdal, which they claimed were marketed for off-label, unapproved uses with children.
The company denied the allegations.
In 1993, the US Food and Drug Administration approved Risperdal for treating schizophrenia and bipolar mania in adults. It was only in 2006 that it was approved for treating irritability associated with autism in children.
The company separately agreed in 2013 to pay $2.2 billion to settle US criminal and civil probes into its marketing of Risperdal and two other drugs.
In May, the US Supreme Court rejected J&J's bid to overturn a $70 million jury verdict against it for its failure to warn about risks associated with using Risperdal.
